SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids

Radiotherapy and Oncology

Volumn 43, Issue 2, 1997, Pages 197-201

  Omura, Motoko ^a   Torigoe, Soichiro ^a   Kubota, Nobuo ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

CPT 11; PLDR; Radiosensitization; SN 38; Spheroids

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DRUG METABOLITE; IRINOTECAN;

ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; HUMAN; HUMAN CELL; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; RADIATION INJURY REPAIR; RADIOSENSITIZATION;

ADENOCARCINOMA; CAMPTOTHECIN; CELL SURVIVAL; COLONIC NEOPLASMS; HUMANS; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0030900289     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)01924-5     Document Type: Article

References (22)

1. Boothman, D.A., Trask, D.K. and Pardee, A.B. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res. 49: 605-612. 1989.
2. Boothman, D.A., Wang, M., Schea, R.A., Burrows, H.L., Strickfaden, S. and Owens, J.K. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24: 939-948, 1992.
3. Durand, R.E. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J. Natl. Cancer Inst. 77: 247-252, 1986.
4. Falk, S.J. and Smith, P.J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int. J. Radiat. Biol. 61: 749-757, 1992.
5. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N. et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10: 16-20, 1992.
6. Gallo, R.C., Whang, P.J. and Adamson, R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 46: 789-795, 1971.
7. Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U. and Stein, H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133: 1710-1715, 1984.
8. Gerdes, J., Schwab, U., Lemke, H. and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31: 13-20, 1983.
9. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51: 4187-4191, 1991.
10. Kim, J.H., Kim, S.H., Kolozsvary, A. and Khil, M.S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22: 515-518, 1992.
11. Kubota, N., Kakehi, M. and Inada, T. Hyperthermic enhancement of cell killing by five platinum complexes in human malignant melanoma cells grown as monolayer cultures and multicellular spheroids. Int. J. Radiat. Oncol. Biol. Phys. 25: 491-497, 1993.
12. Kubota, N., Matsui, K., Sato, S. and Inada, T. Radiation responses of HMV-I human malignant melanoma cells grown in vitro as multicellular spheroids. J. Radiat. Res. 25: 215-224, 1984.
13. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K. and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10: 1225-1229, 1992.
14. Mattern, M.R., Hofmann, G.A., McCabe, F.L. and Johnson, R.K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK and F 104864). Cancer Res. 51: 5813-5816, 1991.
15. Moertel, C.G., Schutt, A.J., Reitemeier, R.J. and Hahn, R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56: 95-101, 1972.
16. Musk, S.R. and Steel, G.G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Br. J. Cancer 62: 364-367, 1990.
17. Ng, C.E., Bussey, A.M. and Raaphorst, G.P. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. Int. J. Radiat. Biol. 66: 49-57, 1994.
18. Olive, P.L. and Durand, R.E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 13: 121-138, 1994.
19. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T. and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. 11: 909-913, 1993.
20. Takeda, S., Shimazoe, T., Kuga, H., Sato, K. and Kono, A. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. Biochem. Biophys. Res. Commun. 188: 70-77, 1992.
21. Takeuchi, S., Dobashi, K., Fujimoto, S., Tanaka, K., Suzuki, M., Terashima. Y., Hasumi, K., Akiya, K., Negishi, Y., Tamaya, T. et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho. 18: 1681-1689, 1991.
22. Takeuchi, S., Takamizawa, H., Takeda, Y., Ohkawa, T., Tamaya, T., Noda, K., Sugawa, T., Sekiba, K., Yakushiji, M. and Taguchi, T. An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho. 18: 579-584, 1991.